Endonovo Therapeutics annual gross margin
2013
2014
2015
2018
2019
2020
2021
2022
2023
2024
Endonovo Therapeutics Gross Margin Growth & History (ENDV)
Endonovo Therapeutics's gross margin was 33.20% for fiscal 2024.
View full Endonovo Therapeutics company overviewEndonovo Therapeutics annual gross margin history
| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2024 | 2024-12-31 | 33.20% | −61.21 pp |
| 2023 | 2023-12-31 | 94.41% | +1.79 pp |
| 2022 | 2022-12-31 | 92.62% | +13.12 pp |
| 2021 | 2021-12-31 | 79.50% | +18.93 pp |
| 2020 | 2020-12-31 | 60.57% | −9.32 pp |
| 2019 | 2019-12-31 | 69.89% | −14.58 pp |
| 2018 | 2018-12-31 | 84.47% | — |
| 2015 | 2015-12-31 | 49.31% | +13.32 pp |
| 2014 | 2014-12-31 | 35.99% | −2.89 pp |
| 2013 | 2013-12-31 | 38.88% | — |
Endonovo Therapeutics quarterly gross margin
Q1.14
Q2.14
Q3.14
Q1.15
Q2.15
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q3 2023 | 2023-09-30 | 45.59% | −17.67 pp |
| Q2 2023 | 2023-06-30 | 100.00% | +58.92 pp |
| Q1 2023 | 2023-03-31 | 95.44% | +26.72 pp |
| Q4 2022 | 2022-12-31 | 95.99% | +2800.11 pp |
| Q3 2022 | 2022-09-30 | 63.26% | +3.09 pp |
| Q2 2022 | 2022-06-30 | 41.08% | −57.27 pp |
| Q1 2022 | 2022-03-31 | 68.71% | −24.03 pp |
| Q4 2021 | 2021-12-31 | −2,704.11% | −2394.99 pp |
| Q3 2021 | 2021-09-30 | 60.17% | −37.93 pp |
| Q2 2021 | 2021-06-30 | 98.35% | +23.67 pp |
| Q1 2021 | 2021-03-31 | 92.74% | +1.72 pp |
| Q4 2020 | 2020-12-31 | −309.12% | −377.34 pp |
| Q3 2020 | 2020-09-30 | 98.10% | +14.61 pp |
| Q2 2020 | 2020-06-30 | 74.68% | +21.83 pp |
| Q1 2020 | 2020-03-31 | 91.02% | +8.17 pp |
| Q4 2019 | 2019-12-31 | 68.22% | −12.63 pp |
| Q3 2019 | 2019-09-30 | 83.48% | +3.72 pp |
| Q2 2019 | 2019-06-30 | 52.86% | −42.87 pp |
| Q1 2019 | 2019-03-31 | 82.85% | −17.15 pp |
| Q4 2018 | 2018-12-31 | 80.85% | — |
| Q3 2018 | 2018-09-30 | 79.76% | — |
| Q2 2018 | 2018-06-30 | 95.72% | — |
| Q1 2018 | 2018-03-31 | 100.00% | — |
| Q2 2015 | 2015-06-30 | 30.31% | −33.70 pp |
| Q1 2015 | 2015-03-31 | 69.98% | +17.55 pp |
| Q3 2014 | 2014-09-30 | 23.32% | — |
| Q2 2014 | 2014-06-30 | 64.01% | — |
| Q1 2014 | 2014-03-31 | 52.43% | — |
Endonovo Therapeutics gross margin trends
Over the last five fiscal years, Endonovo Therapeutics's gross margin decreased from 69.89% to 33.20%, a change of −36.69 percentage points. The latest reported quarter, Q3 2023, shows 45.59%.
About the metric
What gross margin means
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
Calculation and source
How gross margin is calculated
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Endonovo Therapeutics source filings ↗